论文部分内容阅读
目的 观察头孢拉定对奈替米星药代动力学的影响。方法１４例感染患者随机分成单用奈替米星组（ＮＴＭ）和奈替米星＋头孢拉定组（ＮＴＭ＋ＣＰＲ）。采用高效液相色谱一间接光度检测（ＨＰＬＣ－ＩＰＤ）法，测定患者单剂量静脉滴注 ５ ｍｇ ＮＴＭ后的血清药物浓度，并计算主要药动学参数；同时测定尿液药物浓度及药物回收率。结果ＮＴＭ组和ＮＴＭ＋ＣＰＲ组的Ｔ１／１／２β分别为２．４０±１．０１ｈ和 ４．３３± １．４３ｈ（Ｐ＜ ０．０１），ＡＵＣ０～２４ｈ６３．４２± ３０．００ｍｇ／Ｌ·ｈ和 ７８．５４± ３２．８８ｍｇ／Ｌ·ｈ（ｐ＜ ０．０ １），２４ｈ尿中 ＮＴＭ Ｗ收率也有显著性差异。结论 ＮＴＭ＋ＣＰＲ联用时 ＮＴＭ生物利用度增高，尿中回收率下降，连续长期联用将导致体内蓄积。
Objective To observe the effect of cephradine on the pharmacokinetics of netilmicin. Methods Totally 14 infected patients were randomly divided into three groups: nimizumab group (NTM) and netilmicin + cefradine group (NTM + CPR). Serum drug concentrations of single dose of 5 mg NTM were determined by HPLC-IPD method and the main pharmacokinetic parameters were calculated. Meanwhile, the drug concentration of urine and drug recovery . Results T1 / 1 / 2β in NTM group and NTM + CPR group were 2.40 ± 1.01h and 4.33 ± 1.43h (P <0.01), AUC0 ~ 24h63.42 ± 30.00mg / L · h And 78.54 ± 32.88 mg / L · h (p <0.0 1) respectively. There was also a significant difference in the NTM W yield in 24h urine. Conclusions When combined with NTM + CPR, the bioavailability of NTM is increased and the urinary recovery rate is decreased. Continuous long-term use of NTM results in accumulation in vivo.